Pierstorff Erik, Krucoff Max, Ho Dean
Department of Biomedical Engineering, Robert R McCormick School of Engineering and Applied Science, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208, USA. Department of Mechanical Engineering, Robert R McCormick School of Engineering and Applied Science, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208, USA.
Nanotechnology. 2008 Jul 2;19(26):265103. doi: 10.1088/0957-4484/19/26/265103. Epub 2008 May 19.
The realization of optimized therapeutic delivery is impaired by the challenge of localized drug activity and by the dangers of systemic cytotoxicity which often contribute to patient treatment complications. Here we demonstrate the block copolymer-mediated deposition and release of multiple therapeutics which include an LXRα/β agonist 3-((4-methoxyphenyl)amino)-4-phenyl-1-(phenylmethyl)-1H-pyrrole-2,5-dione (LXRa) and doxorubicin hydrochloride (Dox) at the air-water interface via Langmuir-Blodgett deposition, as well as copolymer-mediated potent drug elution toward the Raw 264.7 murine macrophage cell line. The resultant copolymer-therapeutic hybrid serves as a localized platform that can be functionalized with virtually any drug due to the integrated hydrophilic and hydrophobic components of the polymer structure. In addition, the sequestering function of the copolymer to anchor the drugs to implant surfaces can enhance delivery specificity when compared to systemic drug administration. Confirmation of drug functionality was confirmed via suppression of the interleukin 6 (Il-6) and tumor necrosis factor alpha (TNFα) inflammatory cytokines (LXRa), as well as DNA fragmentation analysis (Dox). Furthermore, the fragmentation assays and gene expression analysis demonstrated the innate biocompatibility of the copolymeric material at the gene expression level via the confirmed absence of material-induced apoptosis and a lack of inflammatory gene expression. This modality enables layer-by-layer control of agonist and chemotherapeutic functionalization at the nanoscale for the localization of drug dosage, while simultaneously utilizing the copolymer platform as an anchoring mechanism for drug sequestering, all with an innate material thickness of 4 nm per layer, which is orders of magnitude thinner than existing commercial technologies. Furthermore, these studies comprehensively confirmed the potential translational applicability of copolymeric nanomaterials as localized multitherapeutic thin film platforms.
局部药物活性的挑战以及全身细胞毒性的风险常常导致患者治疗并发症,这阻碍了优化治疗给药的实现。在此,我们展示了通过朗缪尔-布洛杰特沉积法在气-水界面进行的嵌段共聚物介导的多种治疗药物的沉积和释放,这些药物包括LXRα/β激动剂3-((4-甲氧基苯基)氨基)-4-苯基-1-(苯甲基)-1H-吡咯-2,5-二酮(LXRa)和盐酸多柔比星(Dox),以及共聚物介导的向Raw 264.7小鼠巨噬细胞系的强效药物洗脱。所得的共聚物-治疗药物杂化物作为一个局部平台,由于聚合物结构中整合了亲水性和疏水性成分,几乎可以用任何药物进行功能化。此外,与全身给药相比,共聚物将药物锚定在植入物表面的螯合功能可以提高给药特异性。通过抑制白细胞介素6(Il-6)和肿瘤坏死因子α(TNFα)炎性细胞因子(LXRa)以及DNA片段化分析(Dox)证实了药物功能。此外,片段化分析和基因表达分析通过确认不存在材料诱导的细胞凋亡和缺乏炎性基因表达,在基因表达水平上证明了共聚物材料的固有生物相容性。这种方式能够在纳米尺度上对激动剂和化疗功能化进行逐层控制,以实现药物剂量的局部化,同时将共聚物平台用作药物螯合的锚定机制,所有这些的固有材料厚度每层为4纳米,比现有的商业技术薄几个数量级。此外,这些研究全面证实了共聚物纳米材料作为局部多治疗薄膜平台的潜在转化适用性。